Dare Bioscience Inc (DARE)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$0.72+1.11%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · DARE
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance dropped from the top half to the bottom half of its industry over the past month — the reason to own it has weakened.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -1.9% |
| Our one-year growth estimate | diamond | Not available |
Growth built into the price is above our model estimate.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
A comparable growth gap is not available.
The one-year revenue growth assumption on Valuation.
Model as of 2026-09-04 · Compared with 398 industry peers · Company calendar date is not available
DARE — debt issuance
Dated 2026-08-17
Entry into a Material Definitive Agreement. On August 14, 2026, Daré Bioscience, Inc. (the “Company,” “Daré,” “we,” “us,” or “our”) entered into a securities purchase agreement with certain institutional investors relating to the purchase and sale of (i) 4,085,687 shares of our common stock (the “Shares”), (ii) pre-funded warrants to purchase up to an aggregate of 293,894 shares of our common stock (the “Pre-Funded Warrants”), (iii) warrants to purchase up to 4,379,581 shares of our common st…
Why it matters: The launch of DARE to PLAY marks a key revenue milestone for the company. Success here could signal strong market demand for women's health products.
Supportive ifDARE to PLAY generates over $100K in revenue in Q3 2026.
Worry ifDARE to PLAY fails to generate any revenue in Q3 2026.
Why it matters: The launch of DARE to PLAY is key for revenue growth. It signals market acceptance of a new product.
Supportive ifDARE to PLAY dispensing begins in Q3 2026 as planned.
Worry ifDARE to PLAY dispensing does not commence in Q3 2026.
Why it matters: Flora Sync LF5 is the first product revenue for Dare, indicating market acceptance.
Supportive ifFlora Sync LF5 generates revenue in Q3 2026 after its July launch.
Worry ifFlora Sync LF5 does not generate any revenue in Q3 2026.
Why it matters: Revenue from DARE to PLAY marks a key step in building the company's product portfolio.
Supportive ifDARE to PLAY generates product revenue in Q3 2026 as expected.
Worry ifNo revenue is reported from DARE to PLAY in Q3 2026.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$290 on $10,000 · ±2.9% | How much price usually moves either way. |
| Bad day | $812 loss on $10,000 · 8.1% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $7,819 loss on $10,000 · 78.2% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: Following rules is key for keeping the company's listing and investor trust.
Worry ifDare Bioscience fixes the Nasdaq issue and meets listing rules.
Less concerning ifThe company fails to resolve the compliance issue and faces delisting.
Why it matters: Funding from Regulation A offerings is key. It shows the company's financial health.
Watch forDare finishes more Regulation A offerings. These are worth over $1 million.
Also watch forDare fails to complete any new Regulation A offerings in the next quarter.
Why it matters: If healthcare sector growth picks up, it could benefit Dare's performance.
Supportive ifHealthcare sector revenue growth speeds up to 10% or more.
Worry ifHealthcare sector revenue growth keeps slowing below current levels.
Why it matters: Finishing enrollment is important. It helps the trial and gets closer to FDA approval.
Supportive ifEnrollment for the Ovaprene trial reaches 2,500 cycles by the end of 2026.
Worry ifEnrollment does not reach 2,500 cycles by the end of 2026.
Why it matters: Good results could help launch a new contraceptive product.
Supportive ifPositive interim results are reported. This lets the trial continue.
Worry ifNegative results or a halt in the trial are announced.
Why it matters: Earnings beats show strong performance. Consistent beats can improve investor confidence.
Supportive ifNext earnings report shows earnings per share above analyst estimates by at least 10%.
Worry ifThe next earnings report will show earnings per share lower than analyst estimates.
Why it matters: Success in enrollment shows progress in making a possible HPV treatment.
Supportive ifAbout 100 women have joined the DARE-HPV study.
Worry ifEnrollment does not reach target numbers or is delayed.